Anti-inflammatory approaches to ischaemic stroke prevention

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):211-218. doi: 10.1136/jnnp-2016-314817. Epub 2017 Sep 21.

Abstract

Stroke is a major cause of neurological morbidity and mortality. Atherosclerosis is a major contributor to first and recurrent stroke. A growing evidence base indicates that inflammation is a key process in the pathogenesis of atherosclerosis, leading to thromboembolic events. In this review, we summarise the evidence linking inflammation to stroke risk and discuss clinical trials addressing the 'inflammation hypothesis' in coronary disease and stroke. Trial registration number CONVINCE trial ClinicalTrials.gov number; NCT 02898610; Pre-results.

Keywords: stroke.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Brain Ischemia / immunology*
  • Brain Ischemia / prevention & control
  • C-Reactive Protein / immunology
  • Colchicine / therapeutic use
  • Coronary Disease / immunology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Inflammation / immunology*
  • Intracranial Arteriosclerosis / immunology*
  • Plaque, Atherosclerotic / immunology
  • Recurrence
  • Stroke / immunology*
  • Stroke / prevention & control

Substances

  • Anti-Inflammatory Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • C-Reactive Protein
  • Colchicine